Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

14.46
+0.07000.49%
Post-market: 14.460.00000.00%19:08 EDT
Volume:2.79M
Turnover:40.10M
Market Cap:1.48B
PE:-1.57
High:14.63
Open:14.48
Low:13.87
Close:14.39
Loading ...

Biohaven Withdraws Dazluma EU Marketing Application; Shares Fall

MT Newswires Live
·
25 Apr

Biohaven down 12% to $20.60 after pulling European application

TIPRANKS
·
25 Apr

Nyse Halt Biohaven Ltd Ord Add Info Lst $19.270000

THOMSON REUTERS
·
25 Apr

Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21

Insider Monkey
·
24 Apr

Biohaven Ltd. : Deutsche Bank Cuts Target Price to $39 From $69

THOMSON REUTERS
·
14 Apr

Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

PR Newswire
·
05 Apr

Biohaven falls -15.6%

TIPRANKS
·
01 Apr

American Century Companies boosts stake in Biohaven, ETF Daily News says

TIPRANKS
·
31 Mar

Biotech stocks have been hit by 'DOGE' and other fears. Why they're a great value now.

Dow Jones
·
27 Mar

BRIEF-Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board

Reuters
·
26 Mar

Press Release: Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Dow Jones
·
26 Mar

Independent Director of Biohaven John Childs Buys More Stock

Simply Wall St.
·
10 Mar

Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025

Insider Monkey
·
10 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Mobileye, Visionary Holdings, Wolfspeed

Reuters
·
08 Mar

BUZZ-Biohaven drops as Morgan Stanley cuts PT after bipolar drug failure

Reuters
·
08 Mar

Biohaven price target lowered to $63 from $69 at Morgan Stanley

TipRanks
·
07 Mar

Biohaven Ltd : Morgan Stanley Cuts Target Price to $63.00 From $69.00

THOMSON REUTERS
·
07 Mar

Biohaven Is Maintained at Overweight by JP Morgan

Dow Jones
·
05 Mar

Analysts Conflicted on These Healthcare Names: PTC Therapeutics (PTCT), 4D Molecular Therapeutics (FDMT) and Biohaven Ltd. (BHVN)

TIPRANKS
·
05 Mar

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity

Blockhead
·
05 Mar